Although not curative, antiplatelet therapy is an integral component of effective secondary prevention following non-cardioembolic stroke. Previous reviews comparing antiplatelet therapy versus placebo or no antiplatelet therapy in patients at high risk for vascular disease, including those with a previous stroke or TIA, found that patients receiving antiplatelet therapy experienced a significant reduction in serious vascular events (myocardial infarction, stroke, or vascular death) after 3 years compared to control subjects with previous stroke or TIA.
Antiplatelet agents, such as aspirin, aspirin and extended-release dipyridamole, or clopidogrel, may be used to prevent stroke recurrence. Cilostazol, a phosphodiesterase III inhibitor, is often used for stroke prevention in Japan and other Asian countries. Triflusal, which is chemically related to aspirin, is considered to be acceptable first-line antiplatelet agent in some European countries. Important factors to consider when choosing an antiplatelet regimen include the presence of concomitant coronary artery disease or peripheral arterial disease, history of recent acute coronary syndrome, coronary artery or other arterial stenting, other cardiovascular risk factors, stroke subtype, comorbid factors potentially predisposing the patient to bleeding, and any socioeconomic limitations.
The American Heart Association/American Stroke Association evidence-based guidelines on non-cardioembolic ischemic stroke recommend treatment with an antiplatelet agent, including aspirin, 50 to 325 mg/d; the combination of aspirin, 25 mg, plus extendedrelease dipyridamole, 200 mg, twice daily; and clopidogrel, 75 mg/d.
Clopidogrel is a reasonable alternative in patients allergic to aspirin. The addition of aspirin to clopidogrel increases the risk of hemorrhage and is not routinely recommended in patients with ischemic stroke or TIA, unless a specific indication (ie, coronary artery stent or acute coronary syndrome) exists.
In patients who have an ischemic stroke while taking aspirin, there is no evidence that increasing the dose of aspirin provides additional benefit. Although alternative antiplatelet agents are often used, no single agent or combination of agents has been prospectively evaluated in patients who have had an ischemic event while receiving aspirin therapy.
Antiplatelet agents should be avoided in the first 24 hours following administration of intravenous alteplase for acute ischemic stroke. Antiplatelet therapy is recommended over oral anticoagulants in patients with non-cardioembolic ischemic stroke or TIA. However, warfarin or novel oral anticoagulants (NOACs) may be used to prevent stroke recurrence in patients with non-valvular atrial fibrillation.
Warfarin may be used to prevent stroke recurrence in patients with other causes of cardiac emboli (non-septic), and some coagulopathies.
In this retrospective study, the authors compared clopidogrel intiation vs. aspirin re-initiation for vascular risk reduction among ischemic stroke patients on aspirin at the time of their index stroke. Compared to aspirin re-initiation, the authors found a lower occurrence of major adverse cardiovascular events (MACE) and recurrent stroke among patients initiated on clopidogrel.
As acknowledged by the authors, in addition to its retrospective nature, the study has several limitations. While one can surmise the results as "intriguing", clinicians will conclude that the underlying pathophysiology of the index strokes and recurrent strokes were unknown. Basically, we just know that these patients had ischemic strokes but not their stroke subtypes or how their co-morbidities were managed. Likewise, 7% of patients with atrial fibrillation were seemingly treated with antiplatelet therapy, and paradoxically GI bleeding/peptic ulcer disease was considerably more prevalent on the clopidogrel group at baseline. Much more details are needed of the underlying cererbrovascular disease of these patients before one can infer that the next steps are future randomized clinical trials.
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GENERAL COMMENTS
In this study, the authors attempt to address a "hot-issue" in terms of preventing a future stroke or myocardial infarction in patients suffering a stroke while on aspirin. This is of special interest since there is no relevant data from a randomized study. Overall, the methodology, statistical analysis, the presentation of the results are adequately presented. "Aspirin treatment failure" is a plausible term to characterize the inadequacy of preventing a stroke while on aspirin. However, compliance issues regarding primary or secondary prevention treatment regimens involving antihypertensive and lipid lowering agents cannot be assessed as the authors acknowledge.
In the methods section, it appears that this is a nationwide study that included all available eligible patients. Is this the case?
Patients treated with clopidogrel received more frequently lipidlowering therapy. Could this indicate that their follow-up was more meticulously performed and their compliance better?
The findings of the study should be interpreted in the light of the several limitations as described in the pertinent section.
P-values should be provided for table 1.
The legend of figure 1 should be rephrased.
VERSION 1 -AUTHOR RESPONSE
Reviewer 1 Comments Reviewer: Jose Biller, MD, FACP, FAAN, FANA, FAHA Comment: As acknowledged by the authors, in addition to its retrospective nature, the study has several limitations. While one can surmise the results as "intriguing", clinicians will conclude that the underlying pathophysiology of the index strokes and recurrent strokes were unknown. Basically, we just know that these patients had ischemic strokes but not their stroke subtypes or how their comorbidities were managed. Likewise, 7% of patients with atrial fibrillation were seemingly treated with antiplatelet therapy, and paradoxically GI bleeding/peptic ulcer disease was considerably more prevalent on the clopidogrel group at baseline. Much more details are needed of the underlying cererbrovascular disease of these patients before one can infer that the next steps are future randomized clinical trials. Response: Thank you. These points are very well taken. 1. We now have added "We excluded patients with atrial fibrillation, valvular heart disease, or coagulopathy, since anticoagulants, rather than antiplatelet agents, are generally more suitable for secondary stroke prevention among these patients" in the Methods section and "Also, 355 patients were excluded due to history of atrial fibrillation, valvular heart disease, or coagulopathy" in the Results section. 2. We now have added the information on antihypertensive treatment (ACEI/ARB, CCB, diuretics) in each group during follow-up period in Table 1 . We now have included "Patients receiving clopidogrel were more likely to use statins and diuretics during the follow-up period." in the Results section. 3. We now have added "The Taiwan National Health Insurance Bureau provides reimbursement for the use of clopidogrel in ischemic stroke patients who are allergic to aspirin or have peptic ulcer (the latter confirmed by prior or current pan-endoscopy results). Although "aspirin treatment failure" is not one of the pre-specified criteria for clopidogrel use, the Bureau typically provides reimbursement in these circumstances. As such, physicians generally have broad latitude to prescribe clopidogrel or aspirin based on their personal preferences." in the Methods section. We also added "The baseline characteristics between the two groups were not significantly different except that patients receiving clopidogrel were more likely to have gastrointestinal bleeding or peptic ulcer, likely because peptic ulcer is an indication for clopidogrel use under the Taiwan National Health Insurance Bureau reimbursement policy, i.e. treatment confounding by indication" to the Results section.
4. We now have revised the last sentence of the conclusion as "Still, the results should be interpreted in the light of the several limitations as described above. Before considering dedicated randomized clinical trials of clopidogrel initiation vs. aspirin re-initiation among patients with ischemic stroke, prospective cohort studies should explore this issue utilizing more precise information on the underlying mechanism of the index stroke and treatment of post-stroke risk factors."
Reviewer 2 Comments Reviewer: Haralampos Milionis Comment 1: In this study, the authors attempt to address a "hot-issue" in terms of preventing a future stroke or myocardial infarction in patients suffering a stroke while on aspirin. This is of special interest since there is no relevant data from a randomized study. Overall, the methodology, statistical analysis, the presentation of the results are adequately presented. "Aspirin treatment failure" is a plausible term to characterize the inadequacy of preventing a stroke while on aspirin. However, compliance issues regarding primary or secondary prevention treatment regimens involving antihypertensive and lipid lowering agents cannot be assessed as the authors acknowledge. Response: Thank you. We now have added antihypertensive agents and statin use in each group in Table 1 and adjusted these factors in the analysis.
Comment 2: In the methods section, it appears that this is a nationwide study that included all available eligible patients. Is this the case? Response: Thank you. Yes. We now have added "This is a nationwide study that included all available and eligible patients" to the methods section.
Comment 3: Patients treated with clopidogrel received more frequently lipid-lowering therapy. Could this indicate that their follow-up was more meticulously performed and their compliance better? Response: Thank you for raising this point. We of course adjusted for lipid lowering treatment but given the nature of our study we cannot conclusively comment on meticulous aspects of follow up or precise medication adherence. However, we now have added "Patients treated with clopidogrel received lipid-lowering therapy more frequently, but we do not know the exact reason for this. On one hand, it should be pointed out that all included patients had roughly similar compliance since medication possession ratios were > 80%. On the other hand, although there is nationwide regulation antiplatelet drug prescriptions, it is not inconceivable that some doctors who were more willing to use the antiplatelet drug with higher cost (clopidogrel) were also more inclined to prescribe statin drugs." to the limitations paragraph of the Discussion section.
Comment 4: The findings of the study should be interpreted in the light of the several limitations as described in the pertinent section. Response: Thank you. We now have added "Still, the results should be interpreted in the light of the several limitations as described above" in the Conclusions paragraph of the Discussion section.
